NIH awards $8.6 million for bold bid to transform lung transplantation
(University of Virginia Health System) Researchers at the University of Virginia School of Medicine have received more than $8.6 million in federal grants to support efforts that could dramatically increase the number of lungs available for transplant - and then save the lives of the people who receive them.
ConclusionsThis analysis defines center-level trends in lung transplantation after CMS flagging. Contrary to our primary hypothesis, flagging did not result in temporal center-level changes. However, programs on prolonged probation demonstrated reduced activity, which likely indicates a shift to higher performing centers.
ConclusionsSarcopenia was associated with poorer short-term outcome, and sarcopenic overweight with poorer overall survival of lung transplant patients.
In this study we describe 2 cases of successful adult DCD HT performed at our institution using an original protocol.
The continuous-flow centrifugal HeartMate 3 left ventricular assist device (Abbott, Abbott Park, IL) is associated with a low risk of de-novo pump thrombosis. In a previous study (the Minimal AnticoaGulation EvaluatioN To aUgment heMocompatibility [MAGENTUM-1] study, ClinicalTrials.gov No. NCT03078374; funded by Abbott and the Ministry of Health, Czech Republic), we reported results of a prospective, observational, pilot trial of reduced intensity warfarin (target international normalized ratio [INR] range 1.5 –1.9) with aspirin in 15 patients implanted with a HeartMate 3 pump and enrolled after 6 weeks.
Distal intestinal obstruction syndrome (DIOS) is a common complication in patients with cystic fibrosis (CF) . DIOS occurs in 10 to 40% of all CF-patients. The risk of developing DIOS is considered higher in the early post-transplant period due to dehydration, immobility, intake of opiates and post-operative adynamic gut . Patients suffer from prolonged intestinal passage or even gastric paresis due to polymedication leading to chronic constipation long-term following lung transplant (LTX) .
Conditions: Acute Leukemia; CML; Myelodysplasia; Lymphoma Interventions: Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate; Drug: Tacrolimus; Drug: Methotrexate; Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide; Drug: Mycophenolate Mofetil; Drug: Cyclophosphamide Sponsors: Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); ...